Royal Marsden Hospital (Chelsea)

London, Kensington and Chelsea SW3 6JJ

2 studies enrolling now · 4 studies all time

What they study most

Advanced Renal Cell Carcinoma (RCC), Cancer of the Prostate, Hormone Sensitive Prostate Cancer, Medullary Thyroid Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Non-Small Cell Lung Cancer, Prostate Cancer

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) — Recruiting now
• A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer — Running, not enrolling
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) — Running, not enrolling